With a skilled research team and years of experience in Antibody-Drug Conjugates (ADCs) development and production, BOC Sciences' ADCs manufacturing platform provides comprehensive payloads for your ADC projects and promotes clinical trials' advancement. Our highly skilled Ph.D. and M.S. synthetic chemists will help solve the payload development challenges you encounter during research, from biological to chemical payload development.
Fig. 1. Structure of ADCs
(Pharmacology & Therapeutics. 2021; 107917).
ADCs are a therapeutic platform that combines targeted antibodies with cytotoxic drugs, showing significant potential in cancer treatment. The payload of an ADC is a key component, typically a highly cytotoxic compound that can be precisely delivered to cancer cells through the targeting action of the antibody, thereby enhancing efficacy and reducing toxicity to normal cells. The selection of the ADC payload directly affects the treatment's effectiveness and safety, requiring strict evaluation. First, the chemical properties of the payload determine its stability in the body, its release within cells, and its ability to bind to the target antibody. Moreover, the toxicity of the payload must be sufficiently high to ensure effective killing of tumor cells, yet not too potent to cause excessive damage to healthy cells. Common payloads include microtubule inhibitors, DNA-damaging agents, and protein synthesis inhibitors. As research progresses, new payloads continue to emerge, offering better selectivity and stability, driving the continuous development of ADC technology. Overall, the selection and optimization of the ADC payload is a key factor in improving therapeutic efficacy and minimizing side effects.
ADC payloads can be classified into different categories based on their structure and mechanism of action. Each category of payload has its specific application scenarios and therapeutic advantages. Selecting the appropriate category of payload and designing the suitable linker are key to improving ADC efficacy and reducing side effects. Common categories of ADC payloads include:
These payloads can induce tumor cell death by inhibiting microtubule polymerization or stabilizing microtubules, thus blocking cell division. Representative compounds include Maytansinoids and Auristatins.
These drugs work by binding to DNA, disrupting its structure, or inducing strand breaks, thereby inhibiting tumor cell replication and repair, ultimately leading to cell death. Common DNA-damaging agents include Calicheamicin and Doxorubicin.
By blocking protein synthesis within tumor cells, these drugs effectively inhibit tumor cell proliferation. Representative payloads include cytotoxic drugs targeting rRNA.
As a leading company in the field of ADCs, BOC Sciences is able to provide biological payloads customization services such as protein toxin and enzyme toxin development. Our employees rely on advanced technology and knowledge to provide you with the most comprehensive and advanced biological payload development services.
BOC Sciences offers the types of chemical payload development, including microtubule inhibitors development, DNA inhibitors development, DNA topoisomerase inhibitors development, and RNA polymerase inhibitors development. Our complete technical platform and professional technical personnel ensure the reliability and accuracy of all developed products.
BOC Sciences specializes in the development of protein toxins, offering comprehensive services from protein engineering to optimization. Our expertise includes designing potent and targeted protein toxins for therapeutic applications, with a focus on enhancing efficacy, specificity, and stability for advanced biomedical research and treatment solutions.
At BOC Sciences, we offer high-quality ADC payloads that meet stringent GMP standards, ensuring that each product not only delivers exceptional efficacy but also offers outstanding cost-effectiveness. Whether your needs involve custom development or large-scale production, we provide tailored solutions to maximize cost savings while ensuring optimal efficacy. Choose BOC Sciences for peace of mind in your R&D projects!
Our research team consists of highly experienced biochemists and pharmaceutical chemists dedicated to the innovation and optimization of ADC payloads.
By optimizing production processes and material sourcing, we offer high-quality ADC payloads at competitive prices, ensuring cost efficiency while maintaining quality.
We have advanced analytical equipment capable of precisely detecting the synthesis, purification, and characterization of ADC payloads. Using techniques such as MS, HPLC, and NMR, we ensure the product's quality and stability at every production stage.
Our laboratory supports small-scale R&D to mid-scale production, offering customized production capabilities to meet client needs and ensuring smooth progress at every stage.
We have kilogram-scale GMP-compliant production capacity, ensuring high yield, quality, and consistency in large-scale ADC payload manufacturing, supporting commercial production.
We apply cutting-edge technologies, such as PEGylation and antibody conjugation, to enhance the targeting, efficacy, and safety of ADC payloads. We continuously optimize these technologies to improve our clients' market competitiveness.
The determination of ADC payload potency is a critical step in evaluating its antitumor activity and therapeutic potential. Typically, the potency is assessed through in vitro cell activity assays, with the most common method being cell proliferation inhibition assays. These experiments determine the cytotoxicity of the payload by assessing the inhibitory effects of different ADC concentrations on target tumor cells. Common assay techniques include MTT, CellTiter-Glo, and Alamar Blue, which are used for cell viability detection. These methods allow for the quantitative evaluation of ADC toxicity to tumor cells. In addition to cell viability assays, payload potency assessment also includes flow cytometry analysis, apoptosis, and cell cycle analysis, which help to understand the mechanism of action of the payload drug in tumor cells. These tests provide crucial information regarding the toxicity, efficacy, and target sites of the ADC payload, offering theoretical support for ADC optimization. Furthermore, in vivo animal models are often used to evaluate payload potency, particularly through tumor suppression studies to verify its clinical potential. In these studies, the pharmacodynamics and safety of the payload are evaluated together to ensure optimal therapeutic outcomes.
Dual payload ADCs are an advanced ADC technology that combines two different drug payloads in a single molecule. With this design, dual payload ADCs can simultaneously target multiple therapeutic mechanisms, enhancing their tumor-killing effects. Compared to traditional single payload ADCs, dual payload ADCs offer higher therapeutic potential by delivering multiple strikes against tumor cells. For example, a dual payload ADC may include one drug targeting cell division and another inhibiting DNA repair. By utilizing two independent mechanisms of action, dual payload ADCs can effectively overcome tumor cell resistance and significantly improve therapeutic efficacy. The development of dual payload ADCs is still in the clinical research phase, though challenges such as payload release stability and safety persist. Based on this, BOC Sciences also offers dual payload ADC development services, committed to enhancing tumor treatment efficacy through innovative payload designs and precise targeting technologies.
The ADC payload linker is the chemical structure that connects the antibody to the drug payload and plays a crucial role in the performance of the ADC. It not only determines how the drug payload is linked to the antibody but also affects the payload's stability and release mechanism. An ideal linker should possess good chemical stability to ensure that the payload is not prematurely released during transport in the body, while also enabling rapid payload release within tumor cells. Common types of linkers include cleavable linkers , such as those triggered by reductive environments, enzymatic degradation, or pH-sensitive environments. The design of the linker must strike a balance between stability and effective release, avoiding premature toxic release in normal cells while ensuring that the payload can act quickly in target cells. Therefore, selecting the appropriate payload linker is an essential step in optimizing the efficacy and safety of ADCs.
References
